Vertex Pharma: Why I Am Buying This Dip
Vertex Pharmaceuticals reported strong Q3 earnings, yet the stock has pulled back, presenting a buying opportunity. The company's robust pipeline, particularly Suzetrigine for acute pain and CASGEVY gene therapy, positions Vertex for significant growth. Vertex's financial health, with no traditional debt and substantial cash reserves, supports its aggressive push into new therapeutic areas and product launches.
Vertex Pharmaceuticals initiated with a Buy at Citi
Citi initiated coverage of Vertex Pharmaceuticals with a Buy rating and $575 price target. The firm believes Vertex is positioned to remain a leader in the cystic fibrosis, or CF, space, with its current product portfolio of Trikafta, Kalydeco, Orkambi, Symdeko and the anticipated approval of the vanza triple which has a PDUFA goal date of January 2, 2025. The firm sees the vanza triple product taking a "notable portion" of the CF market with $8B sales in 2030, the analyst tells investors.
Why Vertex (VERX) Might be Well Poised for a Surge
Vertex (VERX) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
3 Reasons Growth Investors Will Love Vertex (VERX)
Vertex (VERX) possesses solid growth attributes, which could help it handily outperform the market.
What Makes Vertex (VERX) a Strong Momentum Stock: Buy Now?
Does Vertex (VERX) have what it takes to be a top stock pick for momentum investors? Let's find out.
Vertex: Downgrading To A Hold As Upside Is Limited
Downgrading Vertex to neutral due to limited upside at current valuation of 10x FY25 revenue, despite robust growth outlook and strong performance. 3Q24 results exceeded expectations with $170M revenue, driven by 21% y/y subscription growth and 270 bps gross margin expansion. VERX's growth momentum remains strong, supported by ECC to S/4HANA migration and multi-year ERP upgrade cycle, with significant opportunities ahead.
Vertex (VERX) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates
The headline numbers for Vertex (VERX) give insight into how the company performed in the quarter ended September 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Vertex, Inc. (VERX) Q3 2024 Earnings Call Transcript
Vertex, Inc. (NASDAQ:VERX ) Q3 2024 Earnings Conference Call November 6, 2024 8:30 AM ET Company Participants Joe Crivelli - Vice President, Investor Relations David DeStefano - President & Chief Executive Officer John Schwab - Chief Financial Officer Conference Call Participants Joshua Reilly - Needham Steve Enders - Citi Chris Quintero - Morgan Stanley Alex Sklar - Raymond James Daniel Jester - BMO Capital Markets Samad Samana - Jefferies Jake Roberge - William Blair Rob Oliver - Baird Adam Hotchkiss - Goldman Sachs Brad Reback - Stifel Natalie Howe - Bank of America Patrick Walravens - Citizens JMP Securities Operator Good day, and welcome to the Vertex Inc. Third Quarter 2024 Earnings Conference Call. All participants will be in listen-only mode.
Vertex (VERX) Q3 Earnings and Revenues Surpass Estimates
Vertex (VERX) came out with quarterly earnings of $0.16 per share, beating the Zacks Consensus Estimate of $0.14 per share. This compares to earnings of $0.10 per share a year ago.
Vertex Pharmaceuticals: Strong Execution Continued In Q3 But The Valuation Reflects It
Vertex reported strong Q3 results driven by the growth of the cystic fibrosis franchise and raised the full-year revenue guidance range by $100 million at the mid-point. Casgevy finally generated commercial revenue in Q3 and Vertex continues to work in the background to get treatment centers up and running and patients treated. The VX-880 clinical program is progressing to the pivotal stage and povetacicept generated promising data in membranous nephropathy patients.
Vertex Pharmaceuticals Beats Third-Quarter Estimates As Pain Treatment Looms
Vertex Pharmaceuticals beat third-quarter expectations on Monday. Though the company raised its sales outlook, Vertex stock was muted.
Vertex Pharma lifts annual revenue forecast on cystic fibrosis treatments strength
Vertex Pharmaceuticals raised its annual revenue forecast on Monday after it beat third-quarter estimates on demand for its cystic fibrosis (CF) treatments.
